Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.

Viral N Shah,Amer Al-Karadsheh,Cathy Barnes,Jose Mandry,Samer Nakhle,Karin Wernicke-Panten,Daniel Kramer,Wolfgang Schmider,Suzanne Pierre,Lenore Teichert,Baerbel Rotthaeuser,Bhaswati Mukherjee,Timothy S Bailey

Diabetes, obesity & metabolism（2023）

引用 0|浏览5

暂无评分

摘要

PK exposure of SAR-Asp (switching group) and reference NN-Asp (non-switching group) were similar, supporting interchangeability between these two insulin aspart products.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要